Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Transition to ixazomib-based maintenance following daratumumab-based induction for continuous therapy in newly diagnosed multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXin WangDZDongfeng Zeng

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows improved efficacy and safety transitioning to ixazomib maintenance in newly diagnosed multiple myeloma, indicating favorable long-term treatment potential.

Key Points

  • Median progression-free survival was not reached, with the 2-year rate at 54.72% among newly diagnosed multiple myeloma patients.
  • Among the 59 participants, adverse events primarily included hematologic issues, with neutropenia occurring in 8.4% of cases.
  • The cohort transitioned from daratumumab induction to ixazomib-based maintenance, showing enhanced response rates after the switch.
  • This maintenance strategy highlights the potential for improved prolonged therapy and safety in multiple myeloma management.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1d0https://doi.org/10.1182/blood-2025-7517
View Full Paper
Ask AI
Bookmark
Share